Cerdulatinib
Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)). Reference standards of Cerdulatinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object
(
[pname] => Cerdulatinib
[catalogue_number] => PA 03 3830000
[category_ids] => ,75,76,78,70,82,
[chemical_name] =>
[weight] => 445.54
[form] => C20H27N7O3S
[cas] => 1198300-79-6
[pslug] => 1198300-79-6-cerdulatinib-api-pa033830000
[latest_product] => 0
[linkproducts] => 0
[offers_id] =>
[offers_name] =>
[offers_status] =>
[offers_start_date] =>
[offers_end_date] =>
[pageview] =>
[offers_slug] =>
[offers_product_id] =>
[offers_product_code] =>
[offers_master_id] =>
[offer_percentage] =>
[offers_product_main_cat] =>
)
Catalogue No.:PA 03 3830000
Molecular Formula : C20H27N7O3S
Molecular Weight : 445.54